304 related articles for article (PubMed ID: 29092647)
1. Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia.
Tvito A; Rowe JM
Expert Opin Biol Ther; 2017 Dec; 17(12):1557-1564. PubMed ID: 29092647
[TBL] [Abstract][Full Text] [Related]
2. Inotuzumab ozogamicin for the treatment of patients with acute lymphocytic leukemia.
Choudhry A; O'Brien SM
Drugs Today (Barc); 2017 Dec; 53(12):653-665. PubMed ID: 29517084
[TBL] [Abstract][Full Text] [Related]
3. Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia.
Dahl J; Marx K; Jabbour E
Expert Rev Hematol; 2016; 9(4):329-34. PubMed ID: 26783163
[TBL] [Abstract][Full Text] [Related]
4. Inotuzumab Ozogamicin: A Review in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia.
Al-Salama ZT
Target Oncol; 2018 Aug; 13(4):525-532. PubMed ID: 30090971
[TBL] [Abstract][Full Text] [Related]
5. Inotuzumab Ozogamicin: First Global Approval.
Lamb YN
Drugs; 2017 Sep; 77(14):1603-1610. PubMed ID: 28819740
[TBL] [Abstract][Full Text] [Related]
6. Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia.
Kantarjian HM; DeAngelo DJ; Stelljes M; Martinelli G; Liedtke M; Stock W; Gökbuget N; O'Brien S; Wang K; Wang T; Paccagnella ML; Sleight B; Vandendries E; Advani AS
N Engl J Med; 2016 Aug; 375(8):740-53. PubMed ID: 27292104
[TBL] [Abstract][Full Text] [Related]
7. Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia.
Jain N; O'Brien S; Thomas D; Kantarjian H
Front Biosci (Elite Ed); 2014 Jan; 6(1):40-5. PubMed ID: 24389139
[TBL] [Abstract][Full Text] [Related]
8. Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Yurkiewicz IR; Muffly L; Liedtke M
Drug Des Devel Ther; 2018; 12():2293-2300. PubMed ID: 30087554
[TBL] [Abstract][Full Text] [Related]
9. Inotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia.
Thomas X
Expert Opin Investig Drugs; 2012 Jun; 21(6):871-8. PubMed ID: 22500551
[TBL] [Abstract][Full Text] [Related]
10. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study.
Kantarjian HM; DeAngelo DJ; Advani AS; Stelljes M; Kebriaei P; Cassaday RD; Merchant AA; Fujishima N; Uchida T; Calbacho M; Ejduk AA; O'Brien SM; Jabbour EJ; Zhang H; Sleight BJ; Vandendries ER; Marks DI
Lancet Haematol; 2017 Aug; 4(8):e387-e398. PubMed ID: 28687420
[TBL] [Abstract][Full Text] [Related]
11. Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia.
George B; Kantarjian H; Jabbour E; Jain N
Immunotherapy; 2016 Feb; 8(2):135-43. PubMed ID: 26780449
[TBL] [Abstract][Full Text] [Related]
12. Inotuzumab ozogamicin in relapsed B-cell acute lymphoblastic leukemia.
Thota S; Advani A
Eur J Haematol; 2017 May; 98(5):425-434. PubMed ID: 28152223
[TBL] [Abstract][Full Text] [Related]
13. ADCs Show Promise in Leukemias.
Cancer Discov; 2016 Sep; 6(9):939. PubMed ID: 27388473
[TBL] [Abstract][Full Text] [Related]
14. Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin.
Paul S; Rausch CR; Kantarjian H; Jabbour EJ
Future Oncol; 2017 Oct; 13(25):2233-2242. PubMed ID: 28776425
[TBL] [Abstract][Full Text] [Related]
15. Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin.
Ricart AD
Clin Cancer Res; 2011 Oct; 17(20):6417-27. PubMed ID: 22003069
[TBL] [Abstract][Full Text] [Related]
16. Inotuzumab ozogamicin in the management of acute lymphoblastic leukaemia.
Morley NJ; Marks DI
Expert Rev Anticancer Ther; 2016; 16(2):159-64. PubMed ID: 26654587
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody.
Jabbour E; O'Brien S; Huang X; Thomas D; Rytting M; Sasaki K; Cortes J; Garcia-Manero G; Kadia T; Ravandi F; Pierce S; Kantarjian H
Am J Hematol; 2015 Mar; 90(3):193-6. PubMed ID: 25407953
[TBL] [Abstract][Full Text] [Related]
18. Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial.
Jabbour E; Gökbuget N; Advani A; Stelljes M; Stock W; Liedtke M; Martinelli G; O'Brien S; Wang T; Laird AD; Vandendries E; Neuhof A; Nguyen K; Dakappagari N; DeAngelo DJ; Kantarjian H
Leuk Res; 2020 Jan; 88():106283. PubMed ID: 31790983
[TBL] [Abstract][Full Text] [Related]
19. Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome-Negative B-Precursor ALL.
Stelljes M; Raffel S; Alakel N; Wäsch R; Kondakci M; Scholl S; Rank A; Hänel M; Spriewald B; Hanoun M; Martin S; Schwab K; Serve H; Reiser L; Knaden J; Pfeifer H; Marx J; Sauer T; Berdel WE; Lenz G; Brüggemann M; Gökbuget N; Wethmar K
J Clin Oncol; 2024 Jan; 42(3):273-282. PubMed ID: 37883727
[TBL] [Abstract][Full Text] [Related]
20. Inotuzumab ozogamicin in B-cell precursor acute lymphoblastic leukemia: efficacy, toxicity, and practical considerations.
Rubinstein JD; O'Brien MM
Front Immunol; 2023; 14():1237738. PubMed ID: 37600823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
